Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor

Journal of Clinical Investigation

Volumn 101, Issue 2, 1998, Pages 406-412

  Moscatello, David K ^a   Santra, Manoranjan ^a   Mann, David M ^b,c   McQuillan, David J ^d   Wong, Albert J ^a   Iozzo, Renato V ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HOLLAND LABORATORY   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Biglycan; Cell proliferation; MAP kinase; p21; Proteoglycans

Indexed keywords

DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHO CELL; CONTROLLED STUDY; GROWTH INHIBITION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOGLYCAN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0032518407     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI846     Document Type: Article

References (41)

1. Iozzo, R.V., and A.D. Murdoch. 1996. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J. 10:598-614.
2. Krusius, T., and E. Ruoslahti. 1986. Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc. Natl. Acad. Sci. USA. 83:7683-7687.
3. Day, A.A., C.I. McQuillan, J.D. Termine, and M.R. Young. 1987. Molecular cloning and sequence analysis of the cDNA for small proteoglycan II of bovine bone. Biochem. J. 248:801-805.
4. Fisher, L.W., J.D. Termine, and M.F. Young. 1989. Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J. Biol. Chem. 264:4571-4576.
5. Iozzo, R.V. 1997. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 32:141-174.
6. Toole, B.P., and D.A. Lowther. 1968. The effect of chondroitin sulphate-protein in the formation of collagen fibrils in vitro. Biochem. J. 109:857-866.
7. Vogel, K.G., M. Paulsson, and D. Heinegård. 1984. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem. J. 223:587-597.
8. Danielson, K.G., H. Baribault, D.F. Holmes, H. Graham, K.E. Kadler, and R.V. Iozzo. 1997. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 136:729-743.
9. Adany, R., R. Heimer, B. Caterson, J.M. Sorrell, and R.V. Iozzo. 1990. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J. Biol. Chem. 265:11389-11396.
10. Yamaguchi, Y., D.M. Mann, and E. Ruoslahti. 1990. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature. 346: 281-284.
11. Isaka, Y., D.K. Brees, K. Ikegaya, Y. Kaneda, E. Imai, N.A. Noble, and W.A. Border. 1996. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 2:418-423.
12. Santra, M., T. Skorski, B. Calabretta, E.C. Lattime, and R.V. Iozzo. 1995. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA. 92:7016-7020.
13. De Luca, A., M. Santra, A. Baldi, A. Giordano, and R.V. Iozzo. 1996. Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 271:18961-18965.
14. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
15. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
16. Noda, A., Y. Ning, S.F. Venable, O.M. Pereira-Smith, and J.R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:90-98.
17. Santra, M., D.M. Mann, E.W. Mercer, T. Skorski, B. Calabretta, and R.V. Iozzo. 1997. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 100:149-157.
18. 1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
19. Moscatello, D.K., R.B. Montgomery, P. Sundareshan, H. McDanel, M.Y. Wong, and A.J. Wong. 1996. Transformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. 13:85-96.
20. Mann, D.M., Y. Yamaguchi, M.A. Bourdon, and E. Ruoslahti. 1990. Analysis of glycosaminoglycan substitution in decorin by site-directed mutagenesis. J. Biol. Chem. 265:5317-5323.
21. Hocking, A.M., R.A. Strugnell, P. Ramamurthy, and D.J. McQuillan. 1996. Eukaryotic expression of recombinant biglycan. Post-translational processing and the importance of secondary structure for biological activity. J. Biol. Chem. 271:19571-19577.
22. Ramamurthy, P., A.M. Hocking, and D.J. McQuillan. 1996. Recombinant decorin glycoforms. Purification and structure. J. Biol. Chem. 271:19578-19584.
23. Barnes, D.W. 1982. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J. Cell Biol. 93:1-4.
24. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol. 131:235-242.
25. Schlesinger, J., and A. Ullrich. 1992. Growth factor signaling by receptor tyrosine kinases. Neuron. 9:383-391.
26. Seger, R., and E.G. Krebs. 1995. The MAPK signaling cascade. FASEB J. 9:726-735.
27. Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1782-1788.
28. WAF1/CIP1 mediated by STAT1. Science. 272:719-722.
29. Mohammadi, M., A. Honegger, A. Sorokin, A. Ullrich, J. Schlessinger, and D.R. Hurwitz. 1993. Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. Biochemistry. 32:8742-8748.
30. Weber, I.T., R.W. Harrison, and R.V. Iozzo. 1996. Model structure of decorin and implications for collagen fibrillogenesis. J. Biol. Chem. 271:31767-31770.
31. Border, W.A., N.A. Noble, T. Yamamoto, J.R. Harper, Y. Yamaguchi, M.D. Pierschbacher, and E. Ruoslahti. 1992. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature. 360:361-364.
32. Defize, L.H.K., W.H. Moolenaar, P.T. van der Saag, and S.W. de Laat. 1986. Dissociation of cellular responses to epidermal growth factor using anti-receptor monoclonal antibodies. EMBO J. 5:1187-1192.
33. Daub, H., F.U. Weiss, C. Wallasch, and A. Ullrich. 1996. Role of trans-activation of the EGF receptor in signaling by G-protein-coupled receptors. Nature. 379:557-560.
34. Michieli, P., M. Chedid, D. Lin, J.H. Pierce, W.E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54: 3391-3395.
35. Datto, M.B., Y. Li, J.F. Panus, D.J. Howe, Y. Xiong, and X. Wang. 1995. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA. 92: 5545-5549.
36. WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 56:31-35.
37. Harper, J.W., S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, et al. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
38. Elledge, S.J., J. Winston, and J.W. Harper. 1996. A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol. 6:388-392.
39. LaBaer, J., M.D. Garrett, L.F. Stevenson, J.M. Slingerland, C. Sandhu, H.S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes & Dev. 11:847-862.
40. Koyama, H., E.W. Raines, K.E. Bornfeldt, J.M. Roberts, and R. Ross. 1996. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1069-1078.
41. Assoian, R.K. 1997. Anchorage-dependent cell cycle progression. J. Cell Biol. 136:1-4.